Company profile

Base Therapeutics (Shanghai) Co., Ltd.

Privately held: no public share price (VC-backed gene/cell-editing biotech; A2 round led by Gobi Partners GBA in Sept 2024, no exchange listing. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.taiwannews.com.tw/news/5935194]) · China

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
NK510
Phase 1
TIGITSmall molecule
Non-Small Cell Lung Cancer
NK520
Phase 1
Allogeneic genetically-modified NK cell therapy
Acute Myeloid Leukemia

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.